tiprankstipranks
Market News

FedEx Posts Better-Than-Expected 3Q Results As Sales Outperform; Shares Gain 4.4%

FedEx Corporation’s shares jumped 4.4% in Thursday’s extended trading session as the American multinational delivery services company’s fiscal third-quarter (ended Feb. 28) results surpassed analysts’ expectations. Strong top-line growth, aided by volume growth in US domestic residential package and FedEx International priority services, was the primary driver.

FedEx’s (FDX) 3Q adjusted earnings more than doubled to $3.47 per share on a year-over-year basis and easily beat Street estimates of $3.24 per share. Revenue increased 23% to $21.5 billion and came in well ahead of analysts’ expectations of $19.96 billion.

The company’s operating margin was 4.9% in the quarter, up from 2.8% in the prior-year quarter. (See FedEx stock analysis on TipRanks)

FedEx CEO Frederick W. Smith commented, “We expect demand for our unmatched e-commerce and international express solutions to remain very high for the foreseeable future.”

For fiscal 2021, the company expects EPS to be in the range of $17.60 to $18.20.

On March 12, Credit Suisse analyst Allison Landry decreased the stock’s price target to $350 (32.8% upside potential) from $368 and maintained a Buy rating.

“While margins are typically a focal point of earnings,” Landry thinks “investors will be willing to forgive higher cost/piece inflation so long as improved revenue/piece is sufficient to suggest that core price is going up/surcharges are sticking.”

The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating. That’s based on 13 Buys, 4 Holds, and 1 Sell. The average analyst price target of $323.40 implies 22.7% upside potential to current levels. Shares have increased 10.4% over the past six months.

FedEx scores an 8 of 10 from TipRanks’ Smart Score rating system, indicating that the stock has strong potential to outperform market expectations.

Related News:
Lennar’s 1Q Results Top Analysts’ Expectations As Housing Market Picks Up
Johnson & Johnson’s Single-Dose COVID-19 Vaccine Granted Emergency Use Listing By WHO
CDW Inks Deal To Buy Amplified IT; Street Says Buy

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More